Overview

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pharmacia and Upjohn
Treatments:
Delavirdine
Indinavir
Zidovudine
Criteria
Inclusion Criteria

You may be eligible for this study if you:

- Are HIV-positive.

- Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml.

- Have a CD4 cell count of at least 50 cells/mm3.

- Are at least 14 years old (consent of parent or guardian is required if under 18).

Exclusion Criteria

You will not be eligible for this study if you:

- Have ever taken an anti-HIV drug other than ZDV.

- Have taken ZDV for more than 1 month.